Augmentation in the treatment of restless legs syndrome with transdermal rotigotine

Sleep Medicine

Volumn 13, Issue 6, 2012, Pages 589-597

  Beneš, Heike ^a,b   García Borreguero, Diego ^c   Ferini Strambi, Luigi ^d   Schollmayer, Erwin ^e   Fichtner, Andreas ^e   Kohnen, Ralf ^f,g  

^a Somni bene Institute for Clinical Research and Sleep Medicine   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c SLEEP RESEARCH INSTITUTE   (Spain)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UCB PHARMA   (Belgium)

^f ReSearch Pharmaceutical Services Inc   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Augmentation; Dopamine agonist; Loss of efficacy; Restless legs syndrome; Rotigotine; Transdermal delivery

Indexed keywords

PLACEBO; ROTIGOTINE;

APPLICATION SITE REACTION; ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LOW DRUG DOSE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; CONTROLLED CLINICAL TRIALS AS TOPIC; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; HUMANS; RESTLESS LEGS SYNDROME; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TETRAHYDRONAPHTHALENES; THIOPHENES; UNITED STATES;

EID: 84861933926     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2011.09.016     Document Type: Article

References (37)

1. Garcia-Borreguero D., Allen R.P., Benes H., Earley C., Happe S., Hogl B., et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord 2007, 22(Suppl. 18):S476-S484.
2. Allen R.P., Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996, 19(3):205-213.
3. Garcia-Borreguero D., Allen R.P., Kohnen R., Hogl B., Trenkwalder C., Oertel W., et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007, 8(5):520-530.
4. Trenkwalder C., Kohnen R., Allen R.P., Benes H., Ferini-Strambi L., Garcia-Borreguero D., et al. Clinical trials in restless legs syndrome - recommendations of the European RLS Study Group (EURLSSG). Mov Disord 2007, 22(Suppl. 18):S495-S504.
5. Garcia-Borreguero D., Williams A.M. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 2010, 14(5):339-346.
6. Winkelman J.W., Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004, 5(1):9-14.
7. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4(2):101-119.
8. Garcia-Borreguero D., Kohnen R., Hogl B., Ferini-Strambi L., Hadjigeorgiou G.M., Hornyak M., et al. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007, 8(5):455-463.
9. Trenkwalder C., Collado Seidel V., Kazenwadel J., Wetter T.C., Oertel W., Selzer R., et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?. Mov Disord 2003, 18(10):1184-1189.
10. Trenkwalder C., Benes H., Grote L., Happe S., Hogl B., Mathis J., et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 2007, 22(5):696-703.
11. Hogl B., Garcia-Borreguero D., Kohnen R., Ferini-Strambi L., Hadjigeorgiou G., Hornyak M., et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010, 257(2):230-237.
12. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 2002, (3 Suppl.):S23-S25.
13. Silber M.H., Girish M., Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003, 26(7):819-821.
14. Hogl B., Garcia-Borreguero D., Trenkwalder C., Ferini-Strambi L., Hening W., Poewe W., et al. Efficacy and augmentation during 6months of double-blind pramipexole for restless legs syndrome. Sleep Med 2011, 12(4):351-360.
15. Garcia-Borreguero D., Grunstein R., Sridhar G., Dreykluft T., Montagna P., Dom R., et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007, 8(7-8):742-752.
16. Stiasny-Kolster K., Benes H., Peglau I., Hornyak M., Holinka B., Wessel K., et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004, 63(12):2272-2279.
17. Benes H., Heinrich C.R., Ueberall M.A., Kohnen R. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 2004, 27(4):674-682.
18. Trenkwalder C., Benes H., Poewe W., Oertel W.H., Garcia-Borreguero D., de Weerd A.W., et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008, 7(7):595-604.
19. Hening W.A., Allen R.P., Ondo W.G., Walters A.S., Winkelman J.W., Becker P., et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010 Aug 15, 25(11):1675-1683.
20. Oertel W.H., Benes H., Garcia-Borreguero D., Geisler P., Hogl B., Saletu B., et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008, 9(3):228-239.
21. Oertel W.H., Benes H., Garcia-Borreguero D., Geisler P., Hogl B., Trenkwalder C., et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008, 9(8):865-873.
22. Oertel W., Trenkwalder C., Benes H., Ferini-Strambi L., Hogl B., Poewe W., et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011, 10:710-720.
23. Oertel W.H., Benes H., Garcia-Borreguero D., Hogl B., Poewe W., Montagna P., et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010, 11(9):848-856.
24. Walters A.S., LeBrocq C., Dhar A., Hening W., Rosen R., Allen R.P., et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003, 4(2):121-132.
25. Kohnen R., Stiasny-Kolster K., Oertel W.H., Benes H., Trenkwalder C. Severity rating of Restless Legs Syndrome: validation of the RLS-6 scales. Sleep 2004, 27(Abstract Suppl.):A342.
26. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976. p. 217-22.
27. Kohnen R., Benes H., Heinrich C.R., Kurella B. Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-Qol) questionnaire. Mov Disord 2002, 17(Suppl. 5):P743.
28. Garcia-Borreguero D., Allen R., Kohnen R., Benes H., Winkelman J., Hogl B., et al. Loss of response during long-term treatment of restless legs syndrome: guidelines approved by the International Restless Legs Syndrome Study Group for use in clinical trials. Sleep Med 2010, 11(9):956-957.
29. Paulus W., Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 2006, 5(10):878-886.
30. Garcia-Borreguero D., Hogl B., Ferini-Strambi L., Winkelman J.W., Hill-Zabala C., Allen R.P. Augmentation during treatment with ropinirole in restless legs syndrome. Results from a prospective multicentric study over sixty-six weeks. Neurology 2010, 74(Suppl. 2):288. P02.288.
31. Earley C.J., Allen R.P. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996, 19(10):801-810.
32. Silber M.H., Shepard J.W., Wisbey J.A. Pergolide in the management of restless legs syndrome: an extended study. Sleep 1997, 20(10):878-882.
33. Stiasny K., Wetter T.C., Winkelmann J., Brandenburg U., Penzel T., Rubin M., et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 2001, 56(10):1399-1402.
34. Montplaisir J., Denesle R., Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000, 7(Suppl. 1):27-31.
35. Trenkwalder C., Stiasny-Kolster K., Kupsch A., Oertel W.H., Koester J., Reess J. Controlled withdrawal of pramipexole after 6months of open-label treatment in patients with restless legs syndrome. Mov Disord 2006, 21(9):1404-1410.
36. Evidente V.G. Piribedil for restless legs syndrome: a pilot study. Mov Disord 2001, 16(3):579-581.
37. Montplaisir J., Karrasch J., Haan J., Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006, 21(10):1627-1635.